TR201807340T4 - Çan benzeri reseptör agonistleri içeren immünolojik kompozisyonların intradermal yoldan verilmesi. - Google Patents
Çan benzeri reseptör agonistleri içeren immünolojik kompozisyonların intradermal yoldan verilmesi. Download PDFInfo
- Publication number
- TR201807340T4 TR201807340T4 TR2018/07340T TR201807340T TR201807340T4 TR 201807340 T4 TR201807340 T4 TR 201807340T4 TR 2018/07340 T TR2018/07340 T TR 2018/07340T TR 201807340 T TR201807340 T TR 201807340T TR 201807340 T4 TR201807340 T4 TR 201807340T4
- Authority
- TR
- Turkey
- Prior art keywords
- agonist
- delivery system
- micro
- needle
- benzonaphthyridine
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 21
- 230000001900 immune effect Effects 0.000 title description 2
- 229940044601 receptor agonist Drugs 0.000 title description 2
- 239000000018 receptor agonist Substances 0.000 title description 2
- 230000002163 immunogen Effects 0.000 claims abstract description 23
- 239000000556 agonist Substances 0.000 claims abstract description 11
- 229940044616 toll-like receptor 7 agonist Drugs 0.000 claims description 11
- SWJXWSAKHXBQSY-UHFFFAOYSA-N benzo(c)cinnoline Chemical compound C1=CC=C2C3=CC=CC=C3N=NC2=C1 SWJXWSAKHXBQSY-UHFFFAOYSA-N 0.000 claims description 10
- 102000002689 Toll-like receptor Human genes 0.000 claims description 7
- 108020000411 Toll-like receptor Proteins 0.000 claims description 7
- 239000000427 antigen Substances 0.000 claims description 6
- 102000036639 antigens Human genes 0.000 claims description 6
- 108091007433 antigens Proteins 0.000 claims description 6
- 230000001580 bacterial effect Effects 0.000 claims description 5
- 238000000034 method Methods 0.000 claims description 5
- 241000588650 Neisseria meningitidis Species 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims description 2
- 125000001153 fluoro group Chemical group F* 0.000 claims 3
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 2
- 125000003161 (C1-C6) alkylene group Chemical group 0.000 claims 2
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 claims 2
- 102100039360 Toll-like receptor 4 Human genes 0.000 claims 2
- 125000000732 arylene group Chemical group 0.000 claims 2
- 125000005549 heteroarylene group Chemical group 0.000 claims 2
- 101000763579 Homo sapiens Toll-like receptor 1 Proteins 0.000 claims 1
- 101000669406 Homo sapiens Toll-like receptor 6 Proteins 0.000 claims 1
- 102100027010 Toll-like receptor 1 Human genes 0.000 claims 1
- 102100039387 Toll-like receptor 6 Human genes 0.000 claims 1
- 125000002947 alkylene group Chemical group 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- DAZSWUUAFHBCGE-KRWDZBQOSA-N n-[(2s)-3-methyl-1-oxo-1-pyrrolidin-1-ylbutan-2-yl]-3-phenylpropanamide Chemical compound N([C@@H](C(C)C)C(=O)N1CCCC1)C(=O)CCC1=CC=CC=C1 DAZSWUUAFHBCGE-KRWDZBQOSA-N 0.000 claims 1
- 229940044655 toll-like receptor 9 agonist Drugs 0.000 claims 1
- 241000283707 Capra Species 0.000 abstract 1
- 210000004207 dermis Anatomy 0.000 description 7
- 210000002615 epidermis Anatomy 0.000 description 6
- 238000007918 intramuscular administration Methods 0.000 description 4
- 229960005486 vaccine Drugs 0.000 description 4
- 238000010255 intramuscular injection Methods 0.000 description 3
- 239000007927 intramuscular injection Substances 0.000 description 3
- 210000003491 skin Anatomy 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 2
- 230000028993 immune response Effects 0.000 description 2
- 206010022000 influenza Diseases 0.000 description 2
- 239000010985 leather Substances 0.000 description 2
- 210000003205 muscle Anatomy 0.000 description 2
- 102000005962 receptors Human genes 0.000 description 2
- 108020003175 receptors Proteins 0.000 description 2
- 230000004044 response Effects 0.000 description 2
- 229940031626 subunit vaccine Drugs 0.000 description 2
- 101000669402 Homo sapiens Toll-like receptor 7 Proteins 0.000 description 1
- 102100039390 Toll-like receptor 7 Human genes 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0021—Intradermal administration, e.g. through microneedle arrays, needleless injectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/095—Neisseria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55544—Bacterial toxins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55572—Lipopolysaccharides; Lipid A; Monophosphoryl lipid A
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55583—Polysaccharides
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16171—Demonstrated in vivo effect
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Public Health (AREA)
- Mycology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Wood Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
Abstract
Bir intradermal yoldan verme sistemi, bir TLR agonisti ve immünojen içeren bir immünojenik kompozisyon ve bir mikro-iğne ihtiva eder. İmmünojenik kompozisyon, bir yekpare biyo-degrade olabilir mikro-iğne veya bir yekpare kaplı mikro-iğneden oluşabilir. İntradermal yoldan verme sistemi, bir deri peçi halinde formüle edilebilir.
Description
TARIFNAME
CAN BENZERI RESEPTOR AGONISTLERI ICEREN
IMMUNOLOJIK KOMPOZISYONLARIN INTRADERMAL
YOLDAN VERILMESI
TEKNIK SAHA
Bu bulus, asi uygulama alaninda yer almaktadir.
GEÇMIS TEKNOLOJI
Çan benzeri reseptör (TLR) agonistleri içeren asi kompozisyonlari hali
hazirda elde edilebilir ve bu asilar, intramüsküler enjeksiyon yoluyla
uygulanir. Etkili olmakla birlikte intrami'isküler uygulama, agriya ve
lokal doku hasarina neden olabilir ve intramüsküler enjeksiyon
korkusu yaygindir. Intramüsküler enjeksiyonlar, tip alaninda egim
almis personel tarafindan uygulanmali, çabuk uygulama ve reçetesiz
satisin önüne geçilmelidir. Intramüsküler uygulama, uzun zaman
periyotlarinda stabilite kaybina ugrayabilen sivi formülasyonlarin
kullanilmasini gerektirir.
Weldon ve arkadaslari, 2012 (Effect of adjuvants on responses to skin
immunization by microneedles coated With influenza subunit vaccine.
PloS one, 7(7), e41501), influenza alt birim asisi ile birlikte bir TLR7
ligandi olan iinikiinodun mikro-igneyle verilmesinin, tek basina asiya
kiyasla gelismis immün tepkileri indükledigini buldu.
Bulusuii bir hedefi, TLR agoiiistleri içeren asilari uygulamada farkli
bir yöntem ve özellikle yukarida adi geçen sorunlardan muzdarip
olmayan daha uygun bir yol saglamaktir.
BULUSUN AÇIKLAMASI
Kasifler sasirtici bir sekilde bir Çan benzeri reseptör (TLR) agonisti
içeren immünojenik kompozisyonlarin, intrainüsküler yoldan çok
intradermal yolla verilirse daha iyi bir immün tepkisi
saglayabilecegini kesfetti. Kaslara kiyasla dermis ve epideriniste
TLRleri eksprese eden çok sayida hücre bulunabilir ve bu da, gelismis
tepki saglanmasini açiklayabilir. Ayrica özellikle intradermal yoldan
vermenin, bir cilt peçi gibi bir mikro-igne aygiti seklinde çoklu mikro-
igneler kullanilarak yapildigi durumda intraderinal yoldan verme,
intrainüsküler yoldan verineye göre anlainli sekilde daha az agriya
neden olabilir ve kompozisyonun kendi kendine uygulanmasina daha
kolay izin verebilir.
Bulus, bir yekpare biyo-degrade olabilir mikro-igne içeren bir
intradermal verme sisteini saglar; buradaki mikro-igne, bir
benzonaftiridin TLR7 agonisti ve bir immünojen içerir ve buradaki
immünojen, bir bakteriyel anti jen, örnegin bir Neisseria meningitidis
anti jenidir.
Bir düzenekte TLR7 agonisti, Tl formülüne sahiptir:
Bulus ayrica bir yekpare biyo-degrade olabilir mikro-igne içeren
bulusa ait bir intradermal verme sistemi hazirlanmasina yönelik bir
proses de saglar; buradaki mikro-igne, bir benzonaftiridin TLR7
agonisti ve bir bakteriyel immünojen içerir; buradaki yöntem, a)
immünojen ve benzonaftiridin TLR7 agonistinin karistirilmasiyla
immünojen konsantrasyonunun 10 mg/ml-SO mg/ml arasinda ve
benzonaftiridin TLR7 agonisti konsantrasyonunun 0.1 mg/ml-lO
mg/ml arasinda oldugu bir immünojenik kompozisyon olusturulmasi
ve b) immünojenik kompozisyonun kurutulmasiyla bir yekpare biyo-
degrade olabilir mikro-igne olusturulmasi adimlarini kapsar.
Immünojen konsantrasyonu, lOmg/ml, lSmg/ml, 20mg/ml, 25mg/ml,
30mg/ml, 35mg/ml, 40mg/ml, 45mg/ml veya SOmg/ml olabilir ve
TLR agonisti konsantrasyonu, 0.1 mg/ml, 0.2mg/ml, 0.3mg/ml,
Smg/ml, 9mg/ml veya lOmg/ml olabilir.
Kullanilan anti jen-TLR agonisti orani, lO:l civarinda olabilir.
Intradermal yoldan vermeyi gerçeklestirmenin tercih edilen bir yolu,
bir deri peçidir (Örn., biyo-degrade olabilir bir mikro-igne veya kapli
bir mikro-igne yoluyla) ve bu yüzden bulus ayrica bir immünojenin
intradermal yoldan verilmesine yönelik olup, birçok biyo-degrade
olabilir mikro-igne içeren bir deri peçi ile de ilgilidir; buradaki mikro-
igneler, bir benzonaftiridin TLR7 agonisti ve bakteriyel inimi'inojen
Intradermal yoldan verilen immünojenik kompozisyon, standart
delikli intraderinal ignelerle verilen sivi kompozisyonlarin aksine
tercihen katidir. Kati immünojenik kompozisyonlar, deriye penetre
edebilen ve immünojenik kompozisyonlari intradermal yoldan
verebilen yekpare bir mikro-igne seklinde olabilir. Mikro-ignenin
kendisi, kati immünojenik kompozisyondan olusabilir (bakiniz
asagidaki yekpare biyo-bozunabilir mikro-igneler).
Intradermal yoldan verme
Bir kompozisyonun intradermal yoldan verilmesi islemi,
koinpozisyonun dermise verildigi ancak dermisten kasa geçmedigi
herhangi bir verme modu, örnegin kompozisyonun direkt olarak
dermise verildigi (örn., tami tamina epidermisten dermise geçen bir
igneyle) modlar ve kompozisyonun önce epiderinisin deliiimesiyle
epiderinise verildigi (örn., bir igneyle, burada kompozisyon daha
sonra epidermisten dermise hareket eder) inodlar kullanilarak
gerçeklestirilebilir. Intraderinal yoldan verme, verme sisteminin hem
epidermisten (insanlarda tipik olarak yaklasik lOOum kalinliginda)
hem de dermisten (insaiilarda tipik olarak yaklasik 0.6-3mm
kalinliginda) geçerek penetre ettigi ve kompozisyonun daha sonra
kasa verildigi önceki teknolojiye ait intramüsküler yoldan vermeye
Claims (7)
1. Bir yekpare biyo-degrade olabilir mikro-igne içeren bir intradermal yoldan verme sistemi; buradaki mikro-igne, bir benzonaftiridin TLR7 agonisti ve bir immünojen içerir ve buradaki immünojen, bir bakteriyel anti jendir.
2. Istein l”e göre intraderinal yoldan verine sistemi; buradaki bakteriyel anti jen, bir Neisseria meningitidis anti jenidir.
3. Istem 1 veya 2Sye göre intradermal yoldan verme sistemi; buradaki benzonaftiridin TLR7 agonisti, asagidaki T] formülüne sahiptir: R1, H, Ci-Cöalkil, -C(R5)20H,-L1R5,-L]R6, -L2R5, -LZRÖ, -OLZRS veya L1, -C(O)- veya -O-“dur; L2, Ci-Cöalkilen, Cz-Cöalkenilen, arilen, heteroarilen veya - ((CR4R4)po)q(CH2)p-“dir, burada L2”ye ait Ci-Cöalkilen ve C2- Cöalkenilen istege göre 1 ila 4 floro grubuyla ikame edilir; her bir L3 birbirinden bagimsiz olarak Ci-Cöalkilen ve - ((CR4R4)pO)q(CH2)p- arasindan seçilir; burada L3°e ait Cl-Cöalkilen istege göre 1 ila 4 floro grubu ile ikame edilir; L4, arilen veya heteroarilendir; R2, H veya Cl-Cöalkildir; ve - C(R5)20H arasindan seçilir; her bir R4 birbirinden bagimsiz olarak H ve floro arasindan seçilir; R5, -P(O)(OR9)2°dir, R6, -CF2P(O)(OR9)Z veya -C(O)ORl°”dur; R7, -CF2P(O)(OR9)2 veya -C(O)ORl°”dur; R8, H veya C1-C4alkildir; her bir R9 birbirinden bagimsiz olarak H ve C l-Cöalkil arasindan seçilir; RIO, H veya Ci-C4alkildir; her bir p birbirinden bagimsiz olarak 1, 2, 3, 4, 5 ve 6 arasindan seçilir q, 1, 2, 3 veya 4,tür.
4. lstem 3”e ait intradermal yoldan verme sistemi; burada benzonaftiridin TLR7 agonisti, sunlar arasindan seçilir
5. 1 ila 4 isteinlerinden birine ait intradermal yoldan verme sistemi; 21) bir TLR4 agonisti; b) bir TLRS agoriisti; e) bir TLRl agonisti; d) bir TLR6 agonisti; veya 6) bir TLR9 agonisti. olan bir TLR agonisti de içerir.
6. Istem 5°e ait intradermal vemie sistemi; buradaki TLR4 agonisti, MPL”dir.
7. 1 ila 6 arasi istemlerderi birine göre bir intradermal yoldan verme sistemi hazirlanmasina yönelik bir proses; buradaki yöntem, a) immünojen ve benzonaftiridin TLR7 agonistinin karistirilmasiyla immünojen konsantrasyonunun lOmg/ml-SOmg/ml ve benzonaftiridin TLR7 agonisti konsantrasyonunun 0.1mg/m1-10mg/ml oldugu bir immünojenik kompozisyon olusturulmasi ve b) immünojenik kompozisyonun kurutulmasiyla bir yekpare biyo-degrade olabilir mikro-igne olusturulmasi adimlarini kapsar.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361759751P | 2013-02-01 | 2013-02-01 | |
| EP13169596 | 2013-05-28 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TR201807340T4 true TR201807340T4 (tr) | 2018-06-21 |
Family
ID=48485056
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TR2018/07340T TR201807340T4 (tr) | 2013-02-01 | 2014-01-30 | Çan benzeri reseptör agonistleri içeren immünolojik kompozisyonların intradermal yoldan verilmesi. |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US9827190B2 (tr) |
| EP (1) | EP2950819B1 (tr) |
| JP (1) | JP6411378B2 (tr) |
| CN (1) | CN105188747A (tr) |
| BR (1) | BR112015018014A2 (tr) |
| CA (1) | CA2899787A1 (tr) |
| ES (1) | ES2670863T3 (tr) |
| TR (1) | TR201807340T4 (tr) |
| WO (1) | WO2014118305A1 (tr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140363461A1 (en) * | 2011-09-01 | 2014-12-11 | Fabio Bagnoli | Adjuvanted formulations of staphylococcus aureus antigens |
| EP3283102A4 (en) * | 2015-04-16 | 2018-10-03 | Inventprise, LLC. | Bordetella pertussis immunogenic vaccine compositions |
| AR111760A1 (es) | 2017-05-19 | 2019-08-14 | Novartis Ag | Compuestos y composiciones para el tratamiento de tumores sólidos mediante administración intratumoral |
| JP2018196401A (ja) * | 2017-05-19 | 2018-12-13 | ロレアル | マイクロニードルシート |
| WO2020010016A1 (en) | 2018-07-04 | 2020-01-09 | Sutrovax, Inc. | Self-adjuvanted immunogenic conjugates |
| BR112021025025A2 (pt) * | 2019-06-11 | 2022-02-22 | Glaxosmithkline Biologicals Sa | Formulações de vacinas de mucosa |
| KR20220093120A (ko) * | 2019-10-09 | 2022-07-05 | 백세스 테크놀로지스, 인코포레이티드 | 실크 피브로인-기반 마이크로니들 및 그의 용도 |
| WO2021207281A2 (en) * | 2020-04-06 | 2021-10-14 | Eisai R&D Management Co., Ltd. | Vaccines, adjuvants, and methods of generating an immune response |
Family Cites Families (119)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US112509A (en) | 1871-03-07 | Improvement in medical compounds for treating fever and ague | ||
| US4057685A (en) | 1972-02-02 | 1977-11-08 | Abbott Laboratories | Chemically modified endotoxin immunizing agent |
| US4356170A (en) | 1981-05-27 | 1982-10-26 | Canadian Patents & Development Ltd. | Immunogenic polysaccharide-protein conjugates |
| US4673574A (en) | 1981-08-31 | 1987-06-16 | Anderson Porter W | Immunogenic conjugates |
| EP0114787B1 (de) | 1983-01-25 | 1991-09-25 | Ciba-Geigy Ag | Neue Peptidderivate |
| US4459286A (en) | 1983-01-31 | 1984-07-10 | Merck & Co., Inc. | Coupled H. influenzae type B vaccine |
| US4663160A (en) | 1983-03-14 | 1987-05-05 | Miles Laboratories, Inc. | Vaccines for gram-negative bacteria |
| US4761283A (en) | 1983-07-05 | 1988-08-02 | The University Of Rochester | Immunogenic conjugates |
| US4882317A (en) | 1984-05-10 | 1989-11-21 | Merck & Co., Inc. | Covalently-modified bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers and methods of preparing such polysaccharides and conjugataes and of confirming covalency |
| US4695624A (en) | 1984-05-10 | 1987-09-22 | Merck & Co., Inc. | Covalently-modified polyanionic bacterial polysaccharides, stable covalent conjugates of such polysaccharides and immunogenic proteins with bigeneric spacers, and methods of preparing such polysaccharides and conjugates and of confirming covalency |
| US4808700A (en) | 1984-07-09 | 1989-02-28 | Praxis Biologics, Inc. | Immunogenic conjugates of non-toxic E. coli LT-B enterotoxin subunit and capsular polymers |
| IT1187753B (it) | 1985-07-05 | 1987-12-23 | Sclavo Spa | Coniugati glicoproteici ad attivita' immunogenica trivalente |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| NL8802046A (nl) | 1988-08-18 | 1990-03-16 | Gen Electric | Polymeermengsel met polyester en alkaansulfonaat, daaruit gevormde voorwerpen. |
| DE3841091A1 (de) | 1988-12-07 | 1990-06-13 | Behringwerke Ag | Synthetische antigene, verfahren zu ihrer herstellung und ihre verwendung |
| DE68907045T2 (de) | 1989-01-17 | 1993-12-02 | Eniricerche Spa | Synthetische Peptide und deren Verwendung als allgemeine Träger für die Herstellung von immunogenischen Konjugaten, die für die Entwicklung von synthetischen Impfstoffen geeignet sind. |
| EP0482068A1 (en) | 1989-07-14 | 1992-04-29 | American Cyanamid Company | Cytokine and hormone carriers for conjugate vaccines |
| IT1237764B (it) | 1989-11-10 | 1993-06-17 | Eniricerche Spa | Peptidi sintetici utili come carriers universali per la preparazione di coniugati immunogenici e loro impiego per lo sviluppo di vaccini sintetici. |
| SE466259B (sv) | 1990-05-31 | 1992-01-20 | Arne Forsgren | Protein d - ett igd-bindande protein fraan haemophilus influenzae, samt anvaendning av detta foer analys, vacciner och uppreningsaendamaal |
| ATE128628T1 (de) | 1990-08-13 | 1995-10-15 | American Cyanamid Co | Faser-hemagglutinin von bordetella pertussis als träger für konjugierten impfstoff. |
| US5936076A (en) | 1991-08-29 | 1999-08-10 | Kirin Beer Kabushiki Kaisha | αgalactosylceramide derivatives |
| IT1253009B (it) | 1991-12-31 | 1995-07-10 | Sclavo Ricerca S R L | Mutanti immunogenici detossificati della tossina colerica e della tossina lt, loro preparazione ed uso per la preparazione di vaccini |
| IT1262896B (it) | 1992-03-06 | 1996-07-22 | Composti coniugati formati da proteine heat shock (hsp) e oligo-poli- saccaridi, loro uso per la produzione di vaccini. | |
| IL102687A (en) | 1992-07-30 | 1997-06-10 | Yeda Res & Dev | Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them |
| GB9326174D0 (en) | 1993-12-22 | 1994-02-23 | Biocine Sclavo | Mucosal adjuvant |
| WO1997037026A1 (en) | 1996-04-02 | 1997-10-09 | Smithkline Beecham Corporation | Novel compounds |
| JP2000512487A (ja) | 1996-05-14 | 2000-09-26 | スミスクライン・ビーチャム・コーポレイション | 新規化合物 |
| GB9622660D0 (en) | 1996-10-31 | 1997-01-08 | Biocine Spa | Immunogenic detoxified mutant toxin |
| EP1400592A1 (en) | 1996-10-31 | 2004-03-24 | Human Genome Sciences, Inc. | Streptococcus pneumoniae polynucleotides and sequences |
| GB9713156D0 (en) | 1997-06-20 | 1997-08-27 | Microbiological Res Authority | Vaccines |
| US6800744B1 (en) | 1997-07-02 | 2004-10-05 | Genome Therapeutics Corporation | Nucleic acid and amino acid sequences relating to Streptococcus pneumoniae for diagnostics and therapeutics |
| EP1900818A3 (en) | 1997-11-06 | 2008-06-11 | Novartis Vaccines and Diagnostics S.r.l. | Neisserial antigens |
| AU1537699A (en) | 1997-11-26 | 1999-06-15 | Bioresearch Ireland a division of Eolas - The Irish Science and Technology Agency | Extracellular matrix-binding proteins from (staphylococcus aureus) |
| AU1979599A (en) | 1998-01-14 | 1999-08-02 | Chiron S.P.A. | (neisseria meningitidis) antigens |
| JP2002516251A (ja) | 1998-04-23 | 2002-06-04 | ユーエイビー リサーチ ファンデーション | 肺炎球菌表面プロテインＣ（ＰｓｐＣ）のエピトープ領域およびその菌株選択、ならびにそのための使用法 |
| EP2261356A3 (en) | 1998-05-01 | 2012-01-04 | Novartis Vaccines and Diagnostics, Inc. | Neisseria meningitidis antigens and compositions |
| GB9810193D0 (en) | 1998-05-12 | 1998-07-08 | Smithkline Beecham Biolog | Novel compounds |
| CN1318103A (zh) | 1998-07-27 | 2001-10-17 | 微生物技术有限公司 | 肺炎链球菌的核酸和蛋白质 |
| DE69935986D1 (de) | 1998-07-27 | 2007-06-14 | Sanofi Pasteur Ltd | Streptococcus pneumoniae proteine und nukleinsäuren |
| DE69941574D1 (de) | 1998-08-19 | 2009-12-03 | Baxter Healthcare Sa | Immunogenes beta-propionamido-gebundenes polysaccharid-protein konjugat geeignet als impfstoff und hergestellt bei verwendung von n-acryloyliertem polysaccharid |
| ATE422368T1 (de) | 1998-08-31 | 2009-02-15 | Inhibitex Inc | Multikomponenten impfstoffe gegen staphylococcus aureus |
| MXPA01002120A (es) | 1998-08-31 | 2003-03-27 | Trinity College Dublin | Polipeptidos y polinucleotidos de estafilococo negativo a coagulasa. |
| AU1626199A (en) | 1998-12-04 | 2000-06-26 | Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The | A vi-repa conjugate vaccine for immunization against salmonella typhi |
| GB9828000D0 (en) | 1998-12-18 | 1999-02-10 | Chiron Spa | Antigens |
| ES2322306T3 (es) | 1998-12-21 | 2009-06-18 | Medimmune, Inc. | Proteinas de streptpcpccus pneumoniae y fragmentos inmunogenicos para vacunas. |
| US20030130212A1 (en) | 1999-01-14 | 2003-07-10 | Rossignol Daniel P. | Administration of an anti-endotoxin drug by intravenous infusion |
| US6551600B2 (en) | 1999-02-01 | 2003-04-22 | Eisai Co., Ltd. | Immunological adjuvant compounds compositions and methods of use thereof |
| WO2000056360A2 (en) | 1999-03-19 | 2000-09-28 | Smithkline Beecham Biologicals S.A. | Vaccine against antigens from bacteriae |
| CN100379758C (zh) | 1999-03-26 | 2008-04-09 | 科特克斯(Om)有限公司 | 肺炎链球菌抗原 |
| AU781027B2 (en) | 1999-04-09 | 2005-04-28 | Department Of Health & Human Services | Recombinant toxin a protein carrier for polysaccharide conjugate vaccines |
| ES2360296T3 (es) | 1999-06-10 | 2011-06-02 | Medimmune, Llc | Vacunas y proteínas de setreptococcus pneumoniae. |
| EP1075841A1 (en) | 1999-08-13 | 2001-02-14 | Erasmus Universiteit Rotterdam | Pneumococcal vaccines |
| WO2001070955A2 (en) | 2000-03-21 | 2001-09-27 | Elitra Pharmaceuticals, Inc. | Identification of essential genes in prokaryotes |
| GB0007432D0 (en) | 2000-03-27 | 2000-05-17 | Microbiological Res Authority | Proteins for use as carriers in conjugate vaccines |
| CA2407455A1 (en) | 2000-04-27 | 2001-11-01 | Medimmune, Inc. | Immunogenic pneumococcal protein and vaccine compositions thereof |
| AU2001276619A1 (en) | 2000-07-03 | 2002-01-14 | Chiron S.P.A. | Immunisation against chlamydia pneumoniae |
| US20040091495A1 (en) | 2000-07-20 | 2004-05-13 | Lars Bjorck | Protein |
| AU8743001A (en) | 2000-08-28 | 2002-03-13 | Aventis Pasteur | Moraxella polypeptides and corresponding dna fragments and uses thereof |
| GB0022742D0 (en) | 2000-09-15 | 2000-11-01 | Smithkline Beecham Biolog | Vaccine |
| CA2426738A1 (en) | 2000-10-26 | 2002-05-02 | David William Holden | Streptococcal genes |
| EP2189473A3 (en) | 2000-10-27 | 2010-08-11 | Novartis Vaccines and Diagnostics S.r.l. | Nucleic and proteins from streptococcus groups A & B |
| AT410798B (de) | 2001-01-26 | 2003-07-25 | Cistem Biotechnologies Gmbh | Verfahren zur identifizierung, isolierung und herstellung von antigenen gegen ein spezifisches pathogen |
| GB0103424D0 (en) | 2001-02-12 | 2001-03-28 | Chiron Spa | Gonococcus proteins |
| WO2002077183A2 (en) | 2001-03-21 | 2002-10-03 | Elitra Pharmaceuticals, Inc. | Identification of essential genes in microorganisms |
| GB0107661D0 (en) | 2001-03-27 | 2001-05-16 | Chiron Spa | Staphylococcus aureus |
| GB0108079D0 (en) | 2001-03-30 | 2001-05-23 | Microbial Technics Ltd | Protein |
| WO2002085442A1 (en) | 2001-04-19 | 2002-10-31 | Radi Medical Systems Ab | Combined pressure-volume sensor and guide wire assembly |
| US20020193729A1 (en) | 2001-04-20 | 2002-12-19 | Cormier Michel J.N. | Microprojection array immunization patch and method |
| US20030035806A1 (en) | 2001-05-11 | 2003-02-20 | D'ambra Anello J. | Novel meningitis conjugate vaccine |
| US7407664B2 (en) | 2001-05-18 | 2008-08-05 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention | Peptide vaccines against group A streptococci |
| EP2339344A1 (en) | 2001-06-15 | 2011-06-29 | Inhibitex, Inc. | Cross-reactive monoclonal and polyclonal antibodies which recognize surface proteins from coagulase-negative staphylococci and staphylococcus aureus |
| US7410647B2 (en) | 2001-08-02 | 2008-08-12 | University Of Sheffield | Antigenic polypeptides |
| NZ546711A (en) | 2001-12-12 | 2008-06-30 | Chiron Srl | Immunisation against chlamydia trachomatis |
| GB0203403D0 (en) | 2002-02-13 | 2002-04-03 | Chiron Spa | Chlamydia cytotoxic-T cell epitopes |
| EP2275128B1 (en) | 2002-04-02 | 2013-10-16 | Ben Gurion University Of The Negev Research And Development Authority | Protein-based streptococcus pneumoniae vaccines |
| GB0210128D0 (en) | 2002-05-02 | 2002-06-12 | Chiron Spa | Nucleic acids and proteins from streptococcus groups A & B |
| GB0211118D0 (en) | 2002-05-15 | 2002-06-26 | Polonelli Luciano | Vaccines |
| ATE359295T1 (de) | 2002-06-11 | 2007-05-15 | Glaxosmithkline Biolog Sa | Immunogene zusammensetzungen |
| EP1551228B1 (en) | 2002-06-13 | 2012-10-03 | New York University | Synthetic c-glycolipid and its use for treating cancer infectious diseases and autoimmune diseases |
| US6945952B2 (en) | 2002-06-25 | 2005-09-20 | Theraject, Inc. | Solid solution perforator for drug delivery and other applications |
| US20070036828A1 (en) | 2002-09-13 | 2007-02-15 | Chiron Corporation | Group b streptococcus vaccine |
| US20060257852A1 (en) | 2003-04-10 | 2006-11-16 | Chiron Corporation | Severe acute respiratory syndrome coronavirus |
| EP2333114A1 (en) | 2003-04-15 | 2011-06-15 | Intercell AG | S. pneumoniae antigens |
| BRPI0411857A (pt) | 2003-06-26 | 2006-05-23 | Chiron Corp | composições imunogênicas para chlamydia trachomatis |
| PT1648500E (pt) | 2003-07-31 | 2014-10-10 | Novartis Vaccines & Diagnostic | Composições imunogénicas para estreptococos piogenes |
| US7771726B2 (en) | 2003-10-08 | 2010-08-10 | New York University | Use of synthetic glycolipids as universal adjuvants for vaccines against cancer and infectious diseases |
| AU2005214061B2 (en) | 2004-02-18 | 2010-02-04 | Merck Sharp & Dohme Corp. | Polypeptides for inducing a protective immune response against Staphylococcus aureus |
| CN1964626A (zh) | 2004-03-31 | 2007-05-16 | 纽约大学 | 新型合成c－糖脂、其合成及其治疗传染病、癌症和自身免疫性疾病的用途 |
| MX2007003402A (es) | 2004-09-22 | 2007-05-10 | Glaxosmithkline Biolog Sa | Composicion inmunogena para su uso en vacunacion contra estafilococos. |
| US20090004222A1 (en) * | 2004-11-03 | 2009-01-01 | O'hagan Derek | Influenza Vaccination |
| PT2351578T (pt) | 2005-06-27 | 2017-04-07 | Glaxosmithkline Biologicals Sa | Processo para o fabrico de vacinas |
| TWI382019B (zh) | 2005-08-19 | 2013-01-11 | Array Biopharma Inc | 作為類鐸受體（ｔｏｌｌ-ｌｉｋｅ ｒｅｃｅｐｔｏｒ）調節劑之胺基二氮雜呯 |
| CA2629393C (en) | 2005-09-06 | 2014-06-10 | Theraject, Inc. | Solid solution perforator containing drug particle and/or drug-adsorbed particles |
| WO2007053455A2 (en) | 2005-10-28 | 2007-05-10 | Vaxinnate Corporation | Polypeptide ligans for toll-like receptor 4 (tlr4) |
| WO2007059289A1 (en) | 2005-11-18 | 2007-05-24 | 3M Innovative Properties Company | Microneedle arrays and methods of preparing same |
| US8900180B2 (en) | 2005-11-18 | 2014-12-02 | 3M Innovative Properties Company | Coatable compositions, coatings derived therefrom and microarrays having such coatings |
| CN101389768B (zh) | 2005-12-27 | 2015-11-25 | 奥比科技有限责任公司 | 作为疾病的生物标志的生脂腺病毒 |
| EP2368569A3 (en) | 2006-01-18 | 2012-05-02 | University Of Chicago | Compositions and methods related to staphylococcal bacterium proteins |
| US20080031877A1 (en) | 2006-02-17 | 2008-02-07 | Antonello Covacci | Purification of bacterial antigens |
| JP2009531387A (ja) | 2006-03-30 | 2009-09-03 | グラクソスミスクライン バイオロジカルズ ソシエテ アノニム | 免疫原性組成物 |
| AR060187A1 (es) | 2006-03-30 | 2008-05-28 | Glaxosmithkline Biolog Sa | Composicion inmunogenica |
| US20090171314A1 (en) | 2006-04-20 | 2009-07-02 | Ferguson Dennis E | Molded articles comprising microneedle arrays |
| WO2007127976A2 (en) | 2006-05-01 | 2007-11-08 | Georgia Tech Research Corporation | Particle based molding |
| US20080008682A1 (en) | 2006-07-07 | 2008-01-10 | Chong Lee S | Modulators of toll-like receptor 7 |
| US20090182306A1 (en) | 2006-07-21 | 2009-07-16 | Georgia Tech Research Corporation | Microneedle Devices and Methods of Drug Delivery or Fluid Withdrawal |
| WO2008047174A1 (en) | 2006-10-18 | 2008-04-24 | Centre National De La Recherche Scientifique | Alpha-galactosylceramide analogs, their methods of manufacture, intermediate compounds useful in these methods, and pharmaceutical compositions containing them |
| ES2612061T3 (es) | 2007-09-28 | 2017-05-11 | The Queen's University Of Belfast | Dispositivo y método de suministro |
| PE20091236A1 (es) | 2007-11-22 | 2009-09-16 | Astrazeneca Ab | Derivados de pirimidina como immunomoduladores de tlr7 |
| MY150481A (en) | 2008-03-03 | 2014-01-30 | Irm Llc | Compounds and compositions as tlr activity modulators |
| NZ588183A (en) | 2008-03-24 | 2012-05-25 | 4Sc Discovery Gmbh | Novel substituted imidazoquinolines |
| CN102076357A (zh) * | 2008-06-30 | 2011-05-25 | 久光制药株式会社 | 微针装置以及利用微针装置提高流感疫苗的功效性的方法 |
| JP5600104B2 (ja) | 2008-08-01 | 2014-10-01 | ベンティアールエックス ファーマシューティカルズ， インコーポレイテッド | Ｔｏｌｌ様受容体アゴニスト処方物およびその使用 |
| CN102272134B (zh) | 2008-12-09 | 2013-10-16 | 吉里德科学公司 | Toll样受体调节剂 |
| EP2289843A1 (en) | 2009-08-31 | 2011-03-02 | University College Cork-National University of Ireland, Cork | A microneedle device and method for the fabrication thereof |
| JO3257B1 (ar) | 2009-09-02 | 2018-09-16 | Novartis Ag | مركبات وتركيبات كمعدلات لفاعلية tlr |
| WO2011119759A1 (en) * | 2010-03-23 | 2011-09-29 | Irm Llc | Compounds (cystein based lipopeptides) and compositions as tlr2 agonists used for treating infections, inflammations, respiratory diseases etc. |
| BR112012030619A2 (pt) | 2010-06-01 | 2019-09-24 | Novartis Ag | concentração de antígenos de vacina influenza sem liofilização. |
| MX343914B (es) | 2010-09-01 | 2016-11-18 | Glaxosmithkline Biologicals Sa | Adsorcion de inmunopotenciadores en sales metalicas insolubles. |
| WO2012054582A2 (en) * | 2010-10-19 | 2012-04-26 | Trustees Of Tufts College | Silk fibroin-based microneedles and methods of making the same |
-
2014
- 2014-01-30 EP EP14704537.1A patent/EP2950819B1/en active Active
- 2014-01-30 CA CA2899787A patent/CA2899787A1/en not_active Abandoned
- 2014-01-30 US US14/764,997 patent/US9827190B2/en active Active
- 2014-01-30 CN CN201480007165.XA patent/CN105188747A/zh active Pending
- 2014-01-30 TR TR2018/07340T patent/TR201807340T4/tr unknown
- 2014-01-30 BR BR112015018014A patent/BR112015018014A2/pt not_active Application Discontinuation
- 2014-01-30 ES ES14704537.1T patent/ES2670863T3/es active Active
- 2014-01-30 JP JP2015555711A patent/JP6411378B2/ja active Active
- 2014-01-30 WO PCT/EP2014/051860 patent/WO2014118305A1/en active Application Filing
Also Published As
| Publication number | Publication date |
|---|---|
| US9827190B2 (en) | 2017-11-28 |
| ES2670863T3 (es) | 2018-06-01 |
| EP2950819B1 (en) | 2018-03-28 |
| CN105188747A (zh) | 2015-12-23 |
| BR112015018014A2 (pt) | 2017-07-11 |
| CA2899787A1 (en) | 2014-08-07 |
| WO2014118305A1 (en) | 2014-08-07 |
| JP2016508494A (ja) | 2016-03-22 |
| EP2950819A1 (en) | 2015-12-09 |
| JP6411378B2 (ja) | 2018-10-24 |
| US20150366796A1 (en) | 2015-12-24 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| TR201807340T4 (tr) | Çan benzeri reseptör agonistleri içeren immünolojik kompozisyonların intradermal yoldan verilmesi. | |
| Boopathy et al. | Enhancing humoral immunity via sustained-release implantable microneedle patch vaccination | |
| Momtazi-Borojeni et al. | Long-term generation of antiPCSK9 antibody using a nanoliposome-based vaccine delivery system | |
| JP5717268B2 (ja) | ワクチン用のヒト白血球抗原（ｈｌａ）クラスｉまたはｉｉ分子に結合する腫瘍関連ペプチドの新規組成物 | |
| Zhang et al. | Effect of vaccine administration modality on immunogenicity and efficacy | |
| Boks et al. | Controlled release of a model vaccine by nanoporous ceramic microneedle arrays | |
| Laurent et al. | Safety and efficacy of novel dermal and epidermal microneedle delivery systems for rabies vaccination in healthy adults | |
| Chea et al. | Synthesis and preclinical evaluation of QS-21 variants leading to simplified vaccine adjuvants and mechanistic probes | |
| Chen et al. | High immunogenicity of nicotine vaccines obtained by intradermal delivery with safe adjuvants | |
| CN105324128B (zh) | 用于改善存活蛋白疫苗在癌症治疗中的功效的方法 | |
| Tahara et al. | Transcutaneous immunization by a solid-in-oil nanodispersion | |
| CN103961305B (zh) | 经皮给予用wt1肽癌症疫苗带状制剂 | |
| CA2840959A1 (en) | Vaccine composition | |
| Guo et al. | Effective transcutaneous immunization against hepatitis B virus by a combined approach of hydrogel patch formulation and microneedle arrays | |
| ES2834200T3 (es) | Adyuvante para administración transdérmica o transmucosa y preparación farmacéutica que contiene el mismo | |
| Lee et al. | Enhanced anti-tumor immunotherapy by dissolving microneedle patch loaded ovalbumin | |
| Chowdhury et al. | Biocompatible ionic liquids assisted transdermal co-delivery of antigenic protein and adjuvant for cancer immunotherapy | |
| Chen et al. | Laser vaccine adjuvant for cutaneous immunization | |
| Pizzuto et al. | Cationic lipids as one-component vaccine adjuvants: A promising alternative to alum | |
| CY1118826T1 (el) | Διαδικασια για την κατασκευη ενος φαρμακευτικου σκευασματος που περιεχει glatiramer acetate | |
| JP2015529676A5 (tr) | ||
| WO2012054807A3 (en) | Vaccines comprising bisphosphonate and methods of use thereof | |
| KR20140100417A (ko) | 경피 투여용 백신 조성물 | |
| RU2015100889A (ru) | Вакцины для менингококка серогруппы х | |
| Nguyen et al. | Skin immunization with third-generation hepatitis B surface antigen using microneedles |